^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Mesothelin-targeted CAR-T immunotherapy

    Related drugs:
    1m
    Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies. (PubMed, Cancer Discov)
    At the American Association for Cancer Research Annual Meeting, researchers presented data from three separate phase I studies investigating distinct mesothelin-targeted chimeric antigen receptor T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR.
    P1 data • Journal
    |
    MSLN (Mesothelin)
    |
    SynKIR-110
    4ms
    Evaluation of clinical safety, tolerability and efficacy of mesothelin-directed chimeric antigen receptor T cells (FC004) in the treatment of recurrent ovarian epithelial cancer (ChiCTR2500114302)
    P1, N=3, Completed, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1 trial
    |
    MSLN (Mesothelin)
    6ms
    EVEREST-2: A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (clinicaltrials.gov)
    P1/2, N=474, Recruiting, A2 Biotherapeutics Inc. | N=230 --> 474
    Enrollment change
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    9ms
    Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396). (PubMed, J Immunother Cancer)
    Of note, intraperitoneal treatment also exhibits potency against distant disease sites. These findings provide a strong rationale for clinical translation; we are now conducting a clinical trial (NCT06623396) to evaluate intraperitoneal administration of M28z1XXPD1DNR CAR T cells in patients with gastroesophageal cancer peritoneal carcinomatosis.
    P1 data • Preclinical • Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MSLN (Mesothelin) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    ATA2271
    11ms
    Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    MSLN (Mesothelin)
    |
    cyclophosphamide • ATA2271
    11ms
    A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Outpace Bio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    12ms
    A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Outpace Bio, Inc.
    New P1 trial
    1year
    Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Zhejiang University
    New trial
    |
    cyclophosphamide • fludarabine IV • UCLM802
    1year
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=2, Terminated, Takeda | Trial completion date: Oct 2027 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2027 --> Feb 2025; Business decision unrelated to patient safety
    Trial completion date • Trial termination • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    NIB103
    1year
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
    over1year
    A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Verismo Therapeutics | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    SynKIR-110
    over1year
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Arsenal Biosciences, Inc. | N=60 --> 19
    Enrollment change
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015